Immunohistochemical and molecular subtypes of breast cancer in Nigeria
Objective Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2008-07, Vol.110 (1), p.183-188 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 188 |
|---|---|
| container_issue | 1 |
| container_start_page | 183 |
| container_title | Breast cancer research and treatment |
| container_volume | 110 |
| creator | Adebamowo, Clement A. Famooto, Ayotunde Ogundiran, Temidayo O. Aniagwu, Toyin Nkwodimmah, Chibuzor Akang, Effiong E. |
| description | Objective
Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations.
Methods
We prospectively collected and analyzed tumors from consecutive patients presenting to our clinic over an 18 months period from July 2004. During the period, we saw 192 patients without previous histological diagnosis and conducted routine histological and immunohistochemical analysis of their tumors for hormone receptor status.
Results
Most, 65.1% of tumors were ER+, 54.7% were PR+ and 79.7% were HER2 negative. Majority of the tumors, 77.6% were luminal type A, 2.6% were luminal type B, 15.8% were basal type and the remaining 4.0% (6/152) were HER2+/ER− subtype. We found an association between hormone receptor status and tumor grade but not with stage at presentation.
Conclusion
We conclude that there is no difference in the pattern of hormone receptors in breast cancer patients of African origin compared to other populations and urge more use of hormone manipulation for management of breast cancer in this population. |
| doi_str_mv | 10.1007/s10549-007-9694-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71641546</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1493704921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-dd6cb41f70cf8143c06c08958847fcf087ca3e88ca6c22f4c9fd15245f7c1ca73</originalsourceid><addsrcrecordid>eNp1kEtLxDAQx4Mouj4-gBcpgt6qM22ax1HEF4he9Byy08St9LEm7cFvb5ZdXBCEgRnIb_4ZfoydIlwhgLyOCBXXeRpzLTTPqx02w0qWuSxQ7rIZoJC5UCAO2GGMnwCgJeh9doBSSI4aZuz-qeumflg0cRxo4bqGbJvZvs66oXU0tTZkcZqP30sXs8Fn8-BsHDOyPbmQNX320ny40NhjtudtG93Jph-x9_u7t9vH_Pn14en25jmnUusxr2tBc45eAnmFvCQQBEpXSnHpyYOSZEunFFlBReE5aV9jVfDKS0Kysjxil-vcZRi-JhdH0zWRXNva3g1TNBIFx4qLBJ7_AT-HKfTpNlNgwRWkShCuIQpDjMF5swxNZ8O3QTArw2Zt2KzGlWFTpZ2zTfA071y93dgoTcDFBrAxyfQhuWriL1cAR8ByFVSsuZie-mRxe-H_v_8AKkaS3Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212480480</pqid></control><display><type>article</type><title>Immunohistochemical and molecular subtypes of breast cancer in Nigeria</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Adebamowo, Clement A. ; Famooto, Ayotunde ; Ogundiran, Temidayo O. ; Aniagwu, Toyin ; Nkwodimmah, Chibuzor ; Akang, Effiong E.</creator><creatorcontrib>Adebamowo, Clement A. ; Famooto, Ayotunde ; Ogundiran, Temidayo O. ; Aniagwu, Toyin ; Nkwodimmah, Chibuzor ; Akang, Effiong E.</creatorcontrib><description>Objective
Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations.
Methods
We prospectively collected and analyzed tumors from consecutive patients presenting to our clinic over an 18 months period from July 2004. During the period, we saw 192 patients without previous histological diagnosis and conducted routine histological and immunohistochemical analysis of their tumors for hormone receptor status.
Results
Most, 65.1% of tumors were ER+, 54.7% were PR+ and 79.7% were HER2 negative. Majority of the tumors, 77.6% were luminal type A, 2.6% were luminal type B, 15.8% were basal type and the remaining 4.0% (6/152) were HER2+/ER− subtype. We found an association between hormone receptor status and tumor grade but not with stage at presentation.
Conclusion
We conclude that there is no difference in the pattern of hormone receptors in breast cancer patients of African origin compared to other populations and urge more use of hormone manipulation for management of breast cancer in this population.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-007-9694-5</identifier><identifier>PMID: 17674190</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - chemistry ; Breast Neoplasms - classification ; Breast Neoplasms - pathology ; Cancer research ; Epidemiology ; Female ; Gynecology. Andrology. Obstetrics ; Hormones ; Humans ; Immunohistochemistry ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Minority & ethnic groups ; Neoplasm Staging ; Oncology ; Prospective Studies ; Receptor, ErbB-2 - analysis ; Receptors, Estrogen - analysis ; Receptors, Progesterone - analysis ; Tumors</subject><ispartof>Breast cancer research and treatment, 2008-07, Vol.110 (1), p.183-188</ispartof><rights>Springer Science+Business Media, LLC 2007</rights><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-dd6cb41f70cf8143c06c08958847fcf087ca3e88ca6c22f4c9fd15245f7c1ca73</citedby><cites>FETCH-LOGICAL-c399t-dd6cb41f70cf8143c06c08958847fcf087ca3e88ca6c22f4c9fd15245f7c1ca73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-007-9694-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-007-9694-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20410135$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17674190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adebamowo, Clement A.</creatorcontrib><creatorcontrib>Famooto, Ayotunde</creatorcontrib><creatorcontrib>Ogundiran, Temidayo O.</creatorcontrib><creatorcontrib>Aniagwu, Toyin</creatorcontrib><creatorcontrib>Nkwodimmah, Chibuzor</creatorcontrib><creatorcontrib>Akang, Effiong E.</creatorcontrib><title>Immunohistochemical and molecular subtypes of breast cancer in Nigeria</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Objective
Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations.
Methods
We prospectively collected and analyzed tumors from consecutive patients presenting to our clinic over an 18 months period from July 2004. During the period, we saw 192 patients without previous histological diagnosis and conducted routine histological and immunohistochemical analysis of their tumors for hormone receptor status.
Results
Most, 65.1% of tumors were ER+, 54.7% were PR+ and 79.7% were HER2 negative. Majority of the tumors, 77.6% were luminal type A, 2.6% were luminal type B, 15.8% were basal type and the remaining 4.0% (6/152) were HER2+/ER− subtype. We found an association between hormone receptor status and tumor grade but not with stage at presentation.
Conclusion
We conclude that there is no difference in the pattern of hormone receptors in breast cancer patients of African origin compared to other populations and urge more use of hormone manipulation for management of breast cancer in this population.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - chemistry</subject><subject>Breast Neoplasms - classification</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormones</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Minority & ethnic groups</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Prospective Studies</subject><subject>Receptor, ErbB-2 - analysis</subject><subject>Receptors, Estrogen - analysis</subject><subject>Receptors, Progesterone - analysis</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kEtLxDAQx4Mouj4-gBcpgt6qM22ax1HEF4he9Byy08St9LEm7cFvb5ZdXBCEgRnIb_4ZfoydIlwhgLyOCBXXeRpzLTTPqx02w0qWuSxQ7rIZoJC5UCAO2GGMnwCgJeh9doBSSI4aZuz-qeumflg0cRxo4bqGbJvZvs66oXU0tTZkcZqP30sXs8Fn8-BsHDOyPbmQNX320ny40NhjtudtG93Jph-x9_u7t9vH_Pn14en25jmnUusxr2tBc45eAnmFvCQQBEpXSnHpyYOSZEunFFlBReE5aV9jVfDKS0Kysjxil-vcZRi-JhdH0zWRXNva3g1TNBIFx4qLBJ7_AT-HKfTpNlNgwRWkShCuIQpDjMF5swxNZ8O3QTArw2Zt2KzGlWFTpZ2zTfA071y93dgoTcDFBrAxyfQhuWriL1cAR8ByFVSsuZie-mRxe-H_v_8AKkaS3Q</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Adebamowo, Clement A.</creator><creator>Famooto, Ayotunde</creator><creator>Ogundiran, Temidayo O.</creator><creator>Aniagwu, Toyin</creator><creator>Nkwodimmah, Chibuzor</creator><creator>Akang, Effiong E.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080701</creationdate><title>Immunohistochemical and molecular subtypes of breast cancer in Nigeria</title><author>Adebamowo, Clement A. ; Famooto, Ayotunde ; Ogundiran, Temidayo O. ; Aniagwu, Toyin ; Nkwodimmah, Chibuzor ; Akang, Effiong E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-dd6cb41f70cf8143c06c08958847fcf087ca3e88ca6c22f4c9fd15245f7c1ca73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - chemistry</topic><topic>Breast Neoplasms - classification</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormones</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Minority & ethnic groups</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Prospective Studies</topic><topic>Receptor, ErbB-2 - analysis</topic><topic>Receptors, Estrogen - analysis</topic><topic>Receptors, Progesterone - analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adebamowo, Clement A.</creatorcontrib><creatorcontrib>Famooto, Ayotunde</creatorcontrib><creatorcontrib>Ogundiran, Temidayo O.</creatorcontrib><creatorcontrib>Aniagwu, Toyin</creatorcontrib><creatorcontrib>Nkwodimmah, Chibuzor</creatorcontrib><creatorcontrib>Akang, Effiong E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adebamowo, Clement A.</au><au>Famooto, Ayotunde</au><au>Ogundiran, Temidayo O.</au><au>Aniagwu, Toyin</au><au>Nkwodimmah, Chibuzor</au><au>Akang, Effiong E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical and molecular subtypes of breast cancer in Nigeria</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2008-07-01</date><risdate>2008</risdate><volume>110</volume><issue>1</issue><spage>183</spage><epage>188</epage><pages>183-188</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Objective
Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations.
Methods
We prospectively collected and analyzed tumors from consecutive patients presenting to our clinic over an 18 months period from July 2004. During the period, we saw 192 patients without previous histological diagnosis and conducted routine histological and immunohistochemical analysis of their tumors for hormone receptor status.
Results
Most, 65.1% of tumors were ER+, 54.7% were PR+ and 79.7% were HER2 negative. Majority of the tumors, 77.6% were luminal type A, 2.6% were luminal type B, 15.8% were basal type and the remaining 4.0% (6/152) were HER2+/ER− subtype. We found an association between hormone receptor status and tumor grade but not with stage at presentation.
Conclusion
We conclude that there is no difference in the pattern of hormone receptors in breast cancer patients of African origin compared to other populations and urge more use of hormone manipulation for management of breast cancer in this population.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>17674190</pmid><doi>10.1007/s10549-007-9694-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2008-07, Vol.110 (1), p.183-188 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71641546 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Breast cancer Breast Neoplasms - chemistry Breast Neoplasms - classification Breast Neoplasms - pathology Cancer research Epidemiology Female Gynecology. Andrology. Obstetrics Hormones Humans Immunohistochemistry Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Minority & ethnic groups Neoplasm Staging Oncology Prospective Studies Receptor, ErbB-2 - analysis Receptors, Estrogen - analysis Receptors, Progesterone - analysis Tumors |
| title | Immunohistochemical and molecular subtypes of breast cancer in Nigeria |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T01%3A13%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20and%20molecular%20subtypes%20of%20breast%20cancer%20in%20Nigeria&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Adebamowo,%20Clement%20A.&rft.date=2008-07-01&rft.volume=110&rft.issue=1&rft.spage=183&rft.epage=188&rft.pages=183-188&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-007-9694-5&rft_dat=%3Cproquest_cross%3E1493704921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212480480&rft_id=info:pmid/17674190&rfr_iscdi=true |